Ligand Pharmaceuticals Inc (LGND): John L Higgins , Chief Executive Officer of Ligand Pharmaceuticals Inc sold 3,000 shares on Sep 22, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $117.34 per share for a total value of $352,020.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 9, 2016, John W Kozarich (director) sold 1,000 shares at $115.00 per share price.On Aug 9, 2016, Matthew W Foehr (President and COO) sold 12,500 shares at $122.14 per share price.Also, On May 19, 2016, Melanie J Herman (Director of Accounting) sold 334 shares at $120.50 per share price.On May 9, 2016, Jason Aryeh (director) sold 25,000 shares at $119.37 per share price.
Ligand Pharmaceuticals: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Ligand Pharmaceuticals which led to swings in the share price. The shares opened for trading at $117.24 and hit $118.44 on the upside , eventually ending the session at $118.16, with a gain of 1.03% or 1.2 points. The heightened volatility saw the trading volume jump to 2,04,256 shares. The 52-week high of the share price is $139.79 and the company has a market cap of $2,464 M . The 52-week low of the share price is at $79.66.
Company has been under the radar of several Street Analysts.Ligand Pharmaceuticals is Downgraded by Deutsche Bank to Sell and the brokerage firm has raised the Price Target to $ 110 from a previous price target of $104 .Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Aug 5, 2016.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company’s technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases such as hepatitis multiple myeloma muscle wasting Alzheimers disease dyslipidemia diabetes anemia epilepsy focal segmental glomerulosclerosis (FSGS) and osteoporosis.